Functional coronary angiography significantly reduced major cardiovascular events by 38% and procedural complications by 37% compared to conventional angiography in patients experiencing a STEMI heart attack with multivessel disease, according to the AIR-STEMI trial presented at the ESC Congress 2026 and published in the New England Journal of Medicine.
Multivessel coronary artery disease affects nearly half of all patients who suffer a ST-segment elevation myocardial infarction (STEMI), a type of heart attack. The AIR-STEMI trial aimed to determine whether utilizing functional coronary angiography could improve outcomes in STEMI patients with multivessel disease.
In Plain English: The Clinical Takeaway
- Targeted Treatment: Instead of treating every visible narrowing in secondary blood vessels based on a flat X-ray image, doctors used 3D imaging to estimate blood flow and find blockages that actually need treatment.
- Fewer Interventions: Patients evaluated with functional angiography underwent PCI procedures on significantly fewer vessels (51.9% versus 94.9%).
Trial Design, Patient Demographics, and Methodology
Conducted across 21 clinical centers in Italy and Pakistan, the investigator-initiated AIR-STEMI trial enrolled 1,823 patients with a median age of 66 years, of whom 24% were women. Following successful percutaneous coronary intervention (PCI) for the culprit lesion, participants were randomized into two distinct management groups.
In the functional angiography cohort, clinicians utilized angiography-derived fractional flow reserve (FFR) calculations. Lesions scoring an FFR value greater than 0.80 were deferred, whereas lesions scoring 0.80 or less were treated with PCI. Conversely, the control group received PCI for any non-culprit lesions with stenosis of at least 50% estimated by conventional angiography.
Associate Professor Simone Biscaglia from the University Hospital of Ferrara in Italy explained the core diagnostic challenge during the trial presentation: Traditional coronary angiography provides a two-dimensional picture of narrowed vessels, which is subjective since it is interpreted by the human eye. Measuring the functional importance of additional blockages during the culprit procedure can be challenging.
By bypassing visual guesswork, the trial demonstrated that a physiology-driven strategy successfully limited overtreatment.
| Metric / Endpoint | Functional Angiography Group | Conventional Angiography Group |
|---|---|---|
| Non-Culprit Vessels Undergoing PCI | 51.9% | 94.9% |
| Reduction in Major Cardiovascular Events | 38% lower risk | Baseline reference |
| Reduction in Procedural Complications | 37% lower risk | Baseline reference |
| Median Follow-Up Duration | 17.9 months | 17.9 months |
Global Health Implications and Regulatory Context
Software and imaging tools capable of calculating angiography-derived FFR offer a practical solution. Because these calculations utilize images already captured during the initial culprit procedure, hospitals can implement physiology-guided assessments. This efficiency translates directly into lower contrast dye loads for patients.
Contraindications & When to Consult a Doctor
Conclusion
The AIR-STEMI data mark a notable evolution in interventional cardiology.
References
- ESC Congress 2026 Hot Line Sessions. European Society of Cardiology Press Office.
- New England Journal of Medicine. AIR-STEMI Trial Primary Results. NEJM Group.
- Mirage News and Brightsurf Medical Coverage. Syndicated Clinical Trial Data, August 2026.
This report does not substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or qualified health provider with any questions regarding a medical condition.
